NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
With its Q4 revenue up 10% YoY (versus the Street’s 5% YoY estimate) and a 45 basis points expansion in its Ebitda margin to 20.7% (20%), Zydus Wellness Ltd. posted a healthy quarterly performance.
Its personal care range (EverYuth, Nycil) posted a good 23% YoY growth, helped by the upswing in consumption demand while food and nutrition posted 6% YoY growth, hurt by price cuts in Nutralite.
Management was optimistic of double-digit revenue growth in FY25, led by innovation, distribution and its international foray and expected margin to revert to 17-18% over the next two years, aided by operating leverage and softer input prices.
We tweak our FY25e/F26e EPS slightly to factor in the Q4 performance and a lower FY25 tax rate.
We retain our long-term view of a double-digit revenue CAGR and margins returning to 18-20% over two-four years.
We retain our Buy with a higher 12-month target price of Rs 2,150, 33 times FY26e EPS (earlier Rs 1,910).
Key risks:
Failure of product launches, unwarranted or pricey bolt-on acquisitions, price-based competition.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
Sonata Software Q2 Review — Long-Term Story Remains Intact, Says IDBI Capital Maintaining 'Hold'
Bharat Forge Q2 Review — ICICI Securities Ups Target Price On Strong Defence Ramp-Up, Improved Outlook
'Buy' Cholamandalam Shares Maintains Axis Securities Post Inline Q2 Results On Improved H2 Outlook
Dabur Q2 Review: Systematix Maintains 'Hold' On Unconvincing Outlook — Check New Target Price
POPULAR